Catalyst PharmaceuticalCPRX
CPRX
About: Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
Employees: 167
0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
98% more call options, than puts
Call options by funds: $490K | Put options by funds: $248K
71% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 35
53% more repeat investments, than reductions
Existing positions increased: 139 | Existing positions reduced: 91
8% more capital invested
Capital invested by funds: $1.9B [Q3] → $2.06B (+$156M) [Q4]
7% more funds holding
Funds holding: 312 [Q3] → 333 (+21) [Q4]
1.27% more ownership
Funds ownership: 80.62% [Q3] → 81.89% (+1.27%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
33%
upside
Avg. target
$33
44%
upside
High target
$35
55%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Baird Joel Beatty 38% 1-year accuracy 15 / 40 met price target | 42%upside $32 | Outperform Maintained | 3 Mar 2025 |
HC Wainwright & Co. Andrew Fein 35% 1-year accuracy 123 / 356 met price target | 55%upside $35 | Buy Reiterated | 28 Feb 2025 |
Stephens & Co. Sudan Loganathan 23% 1-year accuracy 6 / 26 met price target | 46%upside $33 | Overweight Reiterated | 27 Feb 2025 |
B of A Securities Jason Gerberry 43% 1-year accuracy 9 / 21 met price target | 33%upside $30 | Buy Reiterated | 9 Jan 2025 |
Financial journalist opinion
Based on 10 articles about CPRX published over the past 30 days
Positive
Seeking Alpha
1 week ago
Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts
Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven by expanding drug distribution, increasing dosages, and acquiring additional drugs, while downside risk is limited by strong cash flow and exclusivity runways. The base case is very realistic, offering an attractive asymmetric trade payoff with a potential 40% upside, despite risks associated with acquisition-dependent revenue growth.
Neutral
GlobeNewsWire
2 weeks ago
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate in the upcoming Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 being held in Miami, Florida.
Positive
Seeking Alpha
2 weeks ago
Catalyst Pharmaceuticals: Stable Firdapse, Promising Agamree, Fycompa Challenges
Firdapse drives Catalyst Pharmaceuticals, Inc.'s revenue with a 37% CAGR since its 2019 launch, boosted by an FDA-approved 100 mg dose expansion. Agamree targets DMD and has so far generated $46 million in its first 10 months, which does attest to its strong growth potential. However, Fycompa still faces generic competition starting May 2025. So it remains to be seen if they'll achieve a “managed and gradual” revenue decline.
Positive
The Motley Fool
2 weeks ago
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Shares of drugmaker Catalyst Pharmaceuticals (CPRX 5.54%) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter results posted after Wednesday's close were markedly better than expected.
Neutral
Seeking Alpha
2 weeks ago
Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2024 Earnings Call Transcript
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific Officer Gary Ingenito - Chief Medical and Regulatory Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Asim Rana - Truist Securities Benjamin Paluch - Citi Investment Research Joseph Catanzaro - Piper Sandler Joel Beatty - Baird Felix Ampomah - Stephens Operator Greetings, and welcome to the Catalyst Pharmaceuticals Fourth Quarter and Full-Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Positive
Zacks Investment Research
2 weeks ago
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Positive
Zacks Investment Research
3 weeks ago
Catalyst (CPRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Catalyst (CPRX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
3 weeks ago
Catalyst Pharmaceutical (CPRX) Tops Q4 Earnings and Revenue Estimates
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.53 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million, Fueled by Sustained Organic Growth of FIRDAPSE® and Continued Market Adoption of AGAMREE® Pursuing Strategic Investments to Expand Market Presence and Accelerate Growth Full Year 2025 Total Revenues Expected to be Between $545 Million and $565 Million, Reflecting Confidence in Continued Growth Momentum Conference Call and Webcast to be Held on February 27, 2025, at 8:30 AM ET CORAL GABLES, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the fourth quarter and full year 2024 and provided a business update.
Neutral
GlobeNewsWire
1 month ago
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its fourth quarter and full-year 2024 financial results after the market close on Wednesday, February 26, 2025.
Charts implemented using Lightweight Charts™